Nabriva Therapeutics (NBRVF) 10-Q 10 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 30, 2017
Document and Entity Information
Entity Registrant Name	Nabriva Therapeutics AG
Entity Central Index Key	1,641,640
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		2,721,086
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 27,166	$ 32,778
Short-term investments	41,061	51,106
Other receivables	7,448	5,561
Prepaid expenses	903	1,176
Total current assets	76,578	90,621
Property, plant and equipment, net	490	519
Intangible assets, net	224	270
Long-term receivables	424	420
Deferred tax assets	1,232	1,410
Total assets	78,948	93,240
Current liabilities:
Accounts payable	4,337	2,551
Accrued expense and other current liabilities	11,553	13,326
Total current liabilities	15,890	15,877
Non-current liabilities
Long-term debt	203
Other non-current liabilities	134	107
Total non-current liabilities	337	107
Total liabilities	16,227	15,984
Commitments and contingencies (Note 17)
Stockholders' Equity:
Common stock - no par value; 1,389,786 and 1,388,395 shares authorized at December 31, 2016 and March 31, 2017, respectively; 2,719,695 and 2,721,086 shares issued and outstanding at December 31, 2016 and March 31, 2017, respectively	2,946	2,939
Treasury shares - at cost; 0 shares at December 31, 2016 and 0 shares at March 31, 2017, respectively
Additional paid in capital	279,848	279,149
Accumulated other comprehensive income (loss)	(7)	10
Accumulated deficit	(220,066)	(204,842)
Total stockholders' equity	62,721	77,256
Total liabilities and stockholders' equity	$ 78,948	$ 93,240

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2017	Dec. 31, 2016
Consolidated Balance Sheets
Common stock, no par value	$ 0	$ 0
Common stock, authorized shares	1,388,395	1,389,786
Common stock issued shares	2,721,086	2,719,695
Common stock, outstanding shares	2,721,086	2,719,695
Treasury shares, shares	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenues:
Research premium and grant revenue	$ 1,678	$ 1,419
Operating expenses:
Research and development	(12,660)	(13,036)
General and administrative	(4,218)	(3,085)
Total operating expenses	(16,878)	(16,121)
Loss from operations	(15,200)	(14,702)
Other income (expense):
Other income (expense), net	206	998
Interest income	121	88
Interest expense	(1)
Loss before income taxes	(14,874)	(13,616)
Income tax benefit (expense)	(349)	17
Net loss	(15,223)	(13,599)
Other comprehensive income (loss), net of tax
Unrealized gains (losses) on available-for-sale financial assets	(16)	41
Other comprehensive income (loss), net of tax	(16)	41
Comprehensive loss	$ (15,239)	$ (13,558)
Loss per share
Basic (in dollars per share)	$ (5.60)	$ (6.42)
Diluted (in dollars per share)	$ (5.60)	$ (6.42)
Weighted average number of shares:
Basic (in shares)	2,720,423	2,117,895
Diluted (in shares)	2,720,423	2,117,895

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities
Net loss	$ (15,223)	$ (13,599)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other expense, net	(266)	(924)
Non-cash interest income	(30)	(44)
Depreciation and amortisation expense	76	45
Stock-based compensation	684	580
Deferred income taxes	178	(18)
Other, net	86	1
Changes in operating assets and liabilities:
Changes in long-term receivables	(5)	(15)
Changes in other receivables	(1,586)	(1,638)
Changes in accounts payable	1,789	2,235
Changes in accrued expenses and other liabilities	(383)	2,491
Changes in other non-current liabilities	6	8
Changes in income tax liabilities	(10)	(1)
Net cash used in operating activities	(14,684)	(10,879)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(25)	(67)
Proceeds from sales of property, plant and equipment	2
Proceeds from sales of available-for-sale securities	10,000	3,000
Net cash provided by investing activities	9,977	2,933
Cash flows from financing activities
Proceeds from long-term borrowings	229
Proceeds from exercise of stock options	10	29
Equity transaction costs	(1,410)
Net cash provided by (used in) financing activities	(1,171)	29
Effects of foreign currency translation on cash and cash equivalents	266	924
Net decrease in cash and cash equivalents	(5,612)	(6,993)
Cash and cash equivalents at beginning of period	32,778	36,446
Cash and cash equivalents at end of period	$ 27,166	$ 29,453

Organization and Business Activ

Organization and Business Activities	3 Months Ended
	Mar. 31, 2017
Organization and Business Activities
Organization and Business Activities	1. Organization and Business Activities Nabriva Therapeutics AG, together with its 100% owned and consolidated U.S. subsidiary Nabriva Therapeutics US, Inc. and 100% owned and consolidated Irish subsidiary Nabriva Therapeutics Ireland DAC, (“Nabriva”, “the Group” or the “Company”) is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva was incorporated in Austria as a spin-off from Sandoz GmbH in October 2005 and commenced operations in February 2006. The Company’s headquarters are at Leberstrasse 20, 1110 Vienna Austria. Nabriva Therapeutics US, Inc. was founded and began operations in the United States in August 2014. In February 2017, the Company purchased all shares issued in the capital of Hyacintho DAC, a designated activity company incorporated by a nominee company in December 2016 and renamed the company to Nabriva Therapeutics Ireland DAC on April 10, 2017. Liquidity Since its inception, the Company incurred net losses and generated negative cash flows from its operations. To date, it has financed its operations through the sale of equity securities, including its initial public offering of ADSs and private placements of its common shares, convertible debt financings and research and development support from governmental grants and loans. As of March 31, 2017, the Company had cash and cash equivalents and short term investments of $68.2 million. On December 19, 2016, the Company completed a rights offering and a related underwritten offering for the sale of an aggregate of 588,127 common shares resulting in aggregate gross proceeds of approximately $24.8 million and net proceeds to the Company of approximately $20.6 million, after deducting underwriting fees and offering expenses. On September 23, 2015 the Company completed its initial public offering on the NASDAQ Global Market issuing 9,000,000 ADSs at a price to the public of $10.25 per ADS, representing 900,000 of its common shares. Each ADS represents one tenth of a common share. On September 30, 2015 the underwriters of its initial public offering exercised in full their over-allotment option to purchase an additional 1,350,000 ADSs, representing 135,000 common shares, at the initial public offering price of $10.25 per ADS, less underwriting discounts. Including the over-allotment ADSs, the Company sold an aggregate of 10,350,000 ADSs representing 1,035,000 common shares, in its initial public offering, which resulted in gross proceeds of approximately $106.1 million and net proceeds to the Company of approximately $92.4 million, after deducting underwriting discounts and offering expenses. The Company believes that its existing cash, cash equivalents and short-term investments will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2018.The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than it currently expects. While the Company has raised capital in the past, the ability to raise capital in future periods is not considered probable, as defined under the accounting standards. As such, under the requirements of ASC 205-40, management may not consider the potential for future capital raises in their assessment of the Company’s ability to meet its obligations for the next twelve months. This estimate assumes, among other things, that the Company does not obtain any additional funding through grants and clinical trial support, collaboration agreements or debt financings. As such, in the event necessary, the Company believes it has the ability to elect to forego certain discretionary costs in order to reduce its requirement for cash and to maintain its operations for more than twelve months following the issuance of this report. If the Company is unable to raise capital when needed or on attractive terms, it could be forced to delay, reduce or eliminate its research and development programs or any future commercialization effort. Based on current projections, the company anticipates availability of top-line clinical data from LEAP 1, its first Phase 3 clinical trial of lefamulin for community-acquired bacterial pneumonia (“CABP”), in the third quarter of 2017. In addition, the Company expects to complete patient enrollment for LEAP 2, its second Phase 3 clinical trial of lefamulin for CABP, in the fourth quarter of 2017 and anticipates availability of top-line data for LEAP 2 in the first quarter of 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Preparation The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and U.S. Securities and Exchange Commission (“SEC”) regulations for quarterly reporting. The accompanying consolidated financial information as of March 31, 2017 and for the three months ended March 31, 2016 and 2017 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The interim unaudited financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2017 and for the three months ended March 31, 2016 and 2017. The financial data and other information disclosed in these notes related to the three months ended March 31, 2016 and 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods or any future year or period. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 24, 2017. The Company’s significant accounting policies are described in Note 2 of the notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies. Recent Accounting Pronouncements At the time of authorization of these consolidated financial statements for publication, a number of revisions, amendments and interpretations had already been published by the Financial Accounting Standards Board (FASB). None of these are expected to have a significant effect on the consolidated financial statements of the Company, except the following set out below: · In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or US GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate product revenue. · In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU 2014-16 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known, and reasonably knowable, at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the balance sheet classification of deferred taxes and requires that all deferred taxes be presented as noncurrent. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its financial statements and related disclosures. · In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 will be effective for the Company in the first quarter of 2017 and will be applied either prospectively, retrospectively or using a modified retrospective transition approach depending on the area covered in this update. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), in April 2016 issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”), and in May 2016, issued ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting (“ASU 2016-11”) . ASU 2016-08 clarifies principal versus agent considerations relating to when another party, along with the entity, is involved in providing a good or service to a customer. ASU 2016-08 requires an entity to determine whether the nature of its promise is to provide a good or service to a customer, or to arrange for the good or service to be provided to the customer by the other party. This determination is based upon whether the entity controls the good or service before it is transferred to the customer. When the entity that satisfies a performance obligation is the principal, the entity recognizes the gross amount of consideration as revenue. When the entity that satisfies the performance obligation is the agent, it recognizes the amount of any fee or commission as revenue. ASU 2016-10 clarifies the guidance in Topic 606 for identifying performance obligations in a contract as well as the implementation guidance pertaining to revenue recognition related to licensing arrangements. ASU 2016-11 rescinds several SEC Staff Announcements that are codified in Topic 605, including, among other items, guidance relating to accounting for consideration given by a vendor to a customer, as well as accounting for shipping and handling fees and freight services. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In May 2016, the FASB also issued ASU 2016-12, Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), which provides clarification on certain topics within ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), including assessing collectability, presentation of sales taxes, the measurement date for non-cash consideration and completed contracts at transition, as well as providing a practical expedient for contract modifications at transition. The effective date and transition requirements for the amendments in ASU 2016-08, ASU 2016-10 and ASU 2016-12 are the same as the effective date and transition requirements of ASU 2014-09, which is effective for fiscal years, and for interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. This update is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of this ASU is permitted, including in interim periods. The ASU requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the new guidance will have a significant impact on its financial statements and related disclosures. · In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash . ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not expect the adoption of the amendments to have a material effect on its financial statements and related disclosures.

Research Premium and Grant Reve

Research Premium and Grant Revenue	3 Months Ended
	Mar. 31, 2017
Research Premium and Grant Revenue
Research Premium and Grant Revenue	3. Research Premium and Grant Revenue Research premium and grant revenue consists of the following items: Three Months Ended (in thousands) 2016 2017 Research premium $ $ Government grants — Grants from WWFF Total $ $ Research premium and grant revenue comprises (1) the research premium from the Austrian government, (2) grants received from the Austrian Research Promotion Agency ( Österreichische Forschungsförderungsgesellschaft, or FFG ) and the Vienna Business Promotion Fund ( Wiener Wirtschaftsförderungsfonds, or WWFF ) and (3) the benefit of government loans at below-market interest rates. The research premium the Company receives from the Austrian government is calculated at a specified percent of specified research and development cost base. The Company recognizes the research premium, as long as we have incurred research and development expenses. The WWFF grant is paid out through the landlord in the form of a monthly reduction in lease payments and is recognized over the period from grant date in March 2010 until end of the lease termination waiver term in December 2017. All grants are non-refundable as long as the conditions of the grant are met. The Company is and has been in full compliance with the conditions of the grants and all related regulations. The benefit of a government loan at a below-market rate of interest is treated as a government grant. The benefit due to the difference between the market rate of interest and the rate of interest charged by the governmental organization is measured as the difference between the initial carrying value of the loan and the proceeds received. This benefit is deferred, and recognized through profit and loss over the term of the corresponding liabilities.

Research and Development Expens

Research and Development Expenses	3 Months Ended
	Mar. 31, 2017
Research and Development Expenses
Research and Development Expenses	4. Research and Development Expenses Research and development expenses include the following items: Three Months Ended (in thousands) 2016 2017 Research materials and purchased services $ $ Staff costs Other research and development expenses Depreciation and amortization Total $ $ Research materials and purchased services include all expenses for materials and services in respect of research activities. For the three months ended March 31, 2017, other research and development expenses consisted of $0.3 million in infrastructure expenses, $0.3 million in advisory and external consultancy expenses and $0.1 million in intellectual property and trademark related expenses and travel expenses. For the three months ended March 31, 2016, other research and development expenses consisted of $0.3 million in infrastructure expenses, $0.3 million in advisory and external consultancy expenses, $0.1 million in intellectual property and trademark related expenses and $0.1 million in travel expenses.

General and Administrative Expe

General and Administrative Expenses	3 Months Ended
	Mar. 31, 2017
General and Administrative Expenses
General and Administrative Expenses	5. General and Administrative Expenses General and administrative expenses include the following items: Three Months Ended (in thousands) 2016 2017 Other general and administrative expenses $ $ Staff costs Depreciation and amortization Total $ $ For the three months ended March 31, 2017, other general and administrative expenses included the following: $0.7 million of advisory and external consultancy expenses, $0.2 million of tax consulting, payroll accounting, accounting and auditing expenses, $0.4 million in infrastructure expenses, $1.0 million of legal expenses, $0.1 million of travel expenses, $0.1 million in supervisory board fees and expenses and $0.3 million of other expenses. For the three months ended March 31, 2016, other general and administrative expenses included the following: $0.4 million of advisory and external consultancy expenses, $0.1 million of tax consulting, payroll accounting, accounting and auditing expenses, $0.3 million in infrastructure expenses, $0.3 million of legal expenses, $0.1 million of travel expenses, $0.1 million in supervisory board fees and expenses and $0.3 million of other expenses.

Post-employment benefit obligat

Post-employment benefit obligations	3 Months Ended
	Mar. 31, 2017
Post-employment benefit obligations
Post-employment benefit obligations	6. Post-employment benefit obligations As required under Austrian labor law, the Company makes contributions to a state plan classified as defined contribution plan ( Mitarbeitervorsorgekasse ) for its employees in Austria. Monthly contributions to the plan are 1.53% of salary with respect to each employee and are recognized as expense in the period incurred. In the three months ended March 31, 2017 and 2016, contribution costs amounted to $11,000 and $11,000, respectively. For employees of Nabriva Therapeutics US, Inc., the Company makes contributions to a defined contribution plan as defined in subsection 401(k) of the Internal Revenue Code. The Company matches 100% of the first 3% of the employee’s voluntary contribution to the plan and 50% of the next 2% contributed by the employee. Contributions are recognized as expense in the period incurred. In the three months ended March 31, 2017 and 2016 contribution expenses were approximately $51,000 and $32,000, respectively.

Other income (expense), net

Other income (expense), net	3 Months Ended
	Mar. 31, 2017
Other income (expense), net
Other income (expense), net	7. Other income (expense), net Three Months Ended (in thousands) 2016 2017 Foreign exchange gain $ $ Foreign exchange losses ) ) Other Total $ $

Income tax (expense) benefit

Income tax (expense) benefit	3 Months Ended
	Mar. 31, 2017
Income tax (expense) benefit
Income tax (expense) benefit	8. Income tax (expense) benefit In accordance with the FASB Accounting Standard Codification (ASC) Topic No. 270 “Interim Reporting” and ASC Topic No. 740 “Income Taxes” (Topic No. 740) at the end of each interim period, the Company is required to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. For the three months ended March 31, 2017, the Company recorded tax expense of $349,000 and for the three months ended March 31, 2016, the Company recorded a tax benefit of $17,000. As of March 31, 2017 and December 31, 2016, the Company had a non-current deferred tax assets of $1.2 million and $1.4 million, respectively. The deferred tax asset relates to tax attributes of the Company’s U.S. subsidiary, Nabriva Therapeutics US, Inc. The Company maintains a valuation allowance against certain deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits. On the basis of this evaluation, as of March 31, 2017 and December 31, 2016, the Company has recorded a valuation allowance of $58,085 and $54,114, respectively, to recognize only the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight is given to subjective evidence such as the Company’s projections for growth.

Earnings (Loss) per Share

Earnings (Loss) per Share	3 Months Ended
	Mar. 31, 2017
Earnings (Loss) per Share
Earnings (Loss) per Share	9. Earnings (Loss) per Share Basic earnings/losses per share Basic earnings/losses per share is calculated by dividing the net earnings/loss attributable to shareholders by the weighted average number of shares outstanding during the year. Three Months Ended (in thousands, except per share data) 2016 2017 Net loss for the period $ ) $ ) Weighted average number of shares outstanding Excluded treasury shares on March 31 — Basic loss per share $ ) $ ) Diluted earnings/losses per share Diluted earnings/losses per share is calculated by adjusting the weighted average number of shares outstanding to assume conversion of all dilutive potential shares. The effect of 278,579 and 191,496 potentially dilutive share options has been excluded from the diluted loss per share calculations as of March 31, 2017 and 2016, respectively because it would result in a decrease in the loss per share for the period and is therefore not to be treated as dilutive.

Fair Value Measurement

Fair Value Measurement	3 Months Ended
	Mar. 31, 2017
Fair Value Measurement
Fair Value Measurement	10. Fair Value Measurement US GAAP establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: · Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities. · Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (as exchange rates). · Level 3: Valuation techniques that include inputs for the asset or liability that are not based on observable market data (those are unobservable inputs) and significant to the overall fair value measurement. The following table presents the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy: (in thousands) Level 1 Level 2 Level 3 Total As of December 31, 2016 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ (in thousands) Level 1 Level 2 Level 3 Total As of March 31, 2017 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ As of March 31, 2017 and December 31, 2016, the Company held short term investments (see Note 12) classified as both Level 1 and Level 2, and the Company did not hold any Level 3 financial instruments measured at fair value. There were no transfers between Level 1 and 2 in the three months ended March 31, 2017 or the year ended December 31, 2016. There were no changes in valuation techniques during the three months ended March 31, 2017. As of March 31, 2017 and December 31, 2016, the Company did not hold any financial instruments as liabilities that were held at fair value. Other receivables, prepaid expenses, accounts payable and accrued expenses and other current liabilities are carried at their historical cost which approximates fair value due to their short term nature.

Long-term and current receivabl

Long-term and current receivables	3 Months Ended
	Mar. 31, 2017
Long-term and current receivables
Long-term and current receivables	11. Long-term and current receivables (in thousands) As of As of Deposits $ $ Total long-term receivables $ $ Research premium VAT and other taxes Receivables from grant revenue — Other receivables Total current receivables $ $ Total $ $ Long-term receivables relate to rent deposits made on the office building in Vienna, Austria and King of Prussia, Pennsylvania, United States. Current receivables are all due within one year. No receivables are past due or impaired. As of March 31, 2017 and December 31, 2016, no receivables were pledged.

Short-term investments

Short-term investments	3 Months Ended
	Mar. 31, 2017
Short-term investments
Short-term investments	12. Short-term investments The Company’s short-term investments were as follows: As of December 31, 2016 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of March 31, 2017 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of March 31, 2017 and December 31, 2016, the Company’s short-term investments were classified as available-for-sale and comprised a (i) money market fund that invests all of its assets, excluding cash and deposits, in short term U.S. dollar-denominated debt securities, and (ii) a U.S. treasury note.

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended
	Mar. 31, 2017
Cash and Cash Equivalents
Cash and Cash Equivalents	13. Cash and Cash Equivalents Cash and cash equivalents were as follows: (in thousands) As of As of Cash on hand $ — $ — Cash at bank Total cash and cash equivalents $ $

Share-Based Payments

Share-Based Payments	3 Months Ended
	Mar. 31, 2017
Share-Based Payments
Share-Based Payments	14. Share-Based Payments Stock Option Plan 2007 On September 12, 2007 the Company’s management and supervisory boards resolved to implement a stock option plan (“SOP 2007”) for all employees (including members of the management board) with open-ended contracts of employment with the Company and for selected members of the supervisory board of the Company and further participants. The stock option plan became effective on September 28, 2007 and the shareholders of the Company resolved to amend the SOP 2007 on September 17, 2009, May 7, 2010 and June 30, 2015. The total number of options that were eligible to be granted and vested in the beneficiaries under the SOP 2007 did not exceed 29,889 (the overall number of options under the SOP 2007). The options grant the beneficiaries the right to acquire shares in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. On the last day of the last calendar month of the second year of the vesting period, a further 25% of the options are vested. During the third and fourth years of the vesting period, the remaining 50% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Notwithstanding any of the above, the exercise of vested options was only permissible in case of a liquidation event (e.g. sale of 50% or more of the shares or assets of the Company or merger of the Company) or a qualified public offering. Since the closing of the initial public offering of the Company on September 23, 2015 the beneficiaries are entitled to exercise their vested options until the end of the exercise period on September 27, 2017. The beneficiaries are not entitled to transfer vested options except to individuals by way of inheritance or bequest. Options do not entitle beneficiaries to exercise any shareholder rights. Beneficiaries may exercise shareholder rights if and to the extent such beneficiary otherwise holds shares. As of March 31, 2017, the vested option rights outstanding under the SOP 2007 amount to $1,087 and are recorded under additional paid in capital. Movements in the number of share options outstanding and their related weighted average exercise prices concerning the SOP 2007 are as follows: 2017 Stock Option Plan 2007 Weighted Options Aggregate Outstanding as of January 1, 2017 Granted — — Exercised ) Forfeited — — Outstanding as of March 31, 2017 $ Vested and exercisable as of March 31, 2017 $ The total intrinsic value of options exercised during the three months ended March 31, 2017 was $943,000. The weighted average remaining contractual life of all options granted under the SOP 2007 is 0.2 years. Stock-based compensation expense under the Stock Option Plan 2007 was $15,000, for the three months ended March 31, 2017. We did not accrue any income tax benefit under the Stock Option Plan 2007 for the three months ended March 31, 2017. The weighted average share price at the date of exercise of options exercised during the three months ended March 31, 2017 was $97.67. Stock Option Plan 2015 On April 2, 2015, the Company’s shareholders, management board and supervisory board adopted the Stock Option Plan 2015 and the shareholders approved an amended and restated version of the Stock Option Plan 2015 on June 30, 2015. An amendment to the amended and restated Stock Option Plan 2015 was approved by the shareholders on July 22, 2015. The Stock Option Plan 2015 became effective on July 3, 2015 upon the registration with the commercial register in Austria of the conditional capital increase approved by the shareholders on June 30, 2015. The Stock Option Plan 2015 initially provided for the grant of options for up to 95,000 common shares to the Company’s employees, including members of the management board, and to members of the supervisory board. Following the closing of the initial public offering of the Company, the overall number of options increased to 177,499 shares. Following approval by the Company’s shareholders at its 2016 annual general meeting, the number of shares available for issuance under the Stock Option Plan 2015 was increased to 346,235 common shares. Each vested option grants the beneficiary the right to acquire one share in the Company. The vesting period for the options is four years following the grant date. On the last day of the last calendar month of the first year of the vesting period, 25% of the options attributable to each beneficiary are automatically vested. During the second, third and fourth years of the vesting period, the remaining 75% of the options vest on a monthly pro rata basis (i.e. 2.083% per month). Options granted under the Stock Option Plan 2015 have a term of no more than ten years from the beneficiary’s date of participation. The beneficiaries are not entitled to transfer vested options except to individuals by way of inheritance or bequest. Options do not entitle beneficiaries to exercise any shareholder rights. Beneficiaries may only exercise shareholder rights if and to the extent such beneficiary otherwise holds shares. As at March 31, 2017, the vested option rights outstanding under the SOP 2015 amounted to $4,214 and is recorded under additional paid in capital. Movements in the number of share options outstanding and their related weighted average exercise prices under the Stock Option Plan 2015 are as follows: 2017 Stock Option Plan 2015 Weighted Options Aggregate Outstanding as of January 1, 2017 Granted Exercised — — Forfeited ) Outstanding as of March 31, 2017 $ Vested and exercisable as of March 31, 2017 $ Stock-based compensation expense under the Stock Option Plan 2015 was approximately $1.8 million for the three months ended March 31, 2017. The total income tax benefit under the Stock Option Plan 2015 recognized in the statement of operations and comprehensive income (loss) for the three months ended March 31, 2017 was $200,000. The weighted average fair value of the options granted during the three months ended March 31, 2017 was $32.47 per share. The 102,560 options granted in the three months ended March 31, 2017 were valued based on a Black Scholes option pricing model. The significant inputs into the model were as follows: Input parameters Granted on Granted on Grant date share price in $ Exercise price in $ Expected volatility % % Expected term of options 2.2 years 2.2 years Risk-free interest rate -0.777 % -0.718 % Dividend yield — — The expected price volatility is based on historical trading volatility for the publicly traded peer companies under consideration of the remaining life of the options. The weighted average remaining contractual life of the options granted in the three months ended March 31, 2017 is 9.9 years. As of March 31, 2017, there was $8.0 million of total unrecognized compensation expense, related to unvested options granted under the Stock Option Plan 2015, which will be recognized over the weighted —average remaining vesting period of 2.2 years. Founders’ Program 2007 The Founders’ Program 2007 was an additional share-based payment scheme, the beneficiaries of which were Dr. Gerd Ascher and Dr. Rodger Novak. There remain 623 shares available in form of stock options at an exercise price of €1.00 per share granted under the Founders’ Program and otherwise on the same terms and conditions as set out in the Company’s Stock Option Plan 2007. The 623 options vested as follows: 25% of the options (156 shares) vested in November 2007. A further 25% (155 shares) vested in February 2008. The remaining 50% vested during the period from March 2008 to February 2010 on a monthly pro rata basis (i.e., 2.083% per month, or 13 shares per month). The fair value of each of these options at grant date is $144.23 per share. The options are fully vested and have been exercised.

December 2016 Financing

December 2016 Financing	3 Months Ended
	Mar. 31, 2017
December 2016 Financing
December 2016 Financing
December 2016 Financing	15. December 2016 Financing On December 19, 2016, the Company completed a rights offering and a related underwritten offering for the sale of an aggregate of 588,127 common shares resulting in aggregate gross proceeds of approximately $24.8 million and net proceeds to the Company of approximately $20.6 million, after deducting underwriting fees and offering expenses. In the rights offering, holders of American Depositary Shares, or ADSs, received 0.276 ADS rights for each ADS owned of record on November 29, 2016. One ADS right entitled an ADS holder to subscribe for and purchase one new ADS at the subscription price of $4.32 per ADS, the U.S. dollar equivalent of €4.014 per ADS. An aggregate of 1,592,750 ADSs, representing 159,275 common shares, were subscribed for by holders of ADSs. Each ADS represents one tenth of a common share. In the rights offering, holders of common shares received the common share right to subscribe for and purchase 0.276 new common shares, at a subscription price of €40.14 per new common share for each common share owned of record on November 29, 2016. An aggregate of 102,077 new common shares were subscribed for by holders of common shares. Pursuant to an underwriting agreement that the Company entered into with Cantor Fitzgerald & Co., dated December 14, 2016, Cantor Fitzgerald & Co. agreed to purchase 326,775 common shares, representing all of the unsubscribed common shares in the rights offering, at a purchase price of €40.14 per common share for purposes of resale of ADSs representing such unsubscribed common shares.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	3 Months Ended
	Mar. 31, 2017
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	16. Accrued Expenses and Other Liabilities Other non-current liabilities include an obligation to pay jubilee benefits arising under the collective bargaining agreement for the chemical industry, by which employees in Austria are entitled to receive jubilee payments after being employed for a certain number of years. For this obligation a provision of $113,000 and $107,000 has been made as of March 31, 2017 and December 31, 2016, respectively. The Company’s net obligation in respect of the jubilee payments is calculated annually by an independent actuary in accordance with ASC 710-10-25 using the projected unit credit method. The principle actuarial assumptions used were as follows: discount rate of 1.3% and retirement at the age of 61.5-65 for men and 56.5-65 for women, future annual salary increases of 3%. Accrued expenses and other current liabilities include the following: (in thousands) As of As of Research and development related costs $ $ Payroll and related costs Accounting, tax and audit services Other Total other current liabilities $ $

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies
Commitments and Contingencies	17. Commitments and Contingencies Commitments Lease Agreements In March 2007, the Company entered into a lease agreement for an unlimited period starting in December 2007 with CONTRA Liegenschaftsverwaltung GMBH for the use of business and research premises at Leberstrasse 20, 1110 Vienna. Within the first 10 years the contract can only be terminated under certain conditions. The monthly rental fee for the premises and laboratory furniture was $84,000 and $85,000, as of March 31, 2017 and December 31, 2016, respectively, and includes all operating costs. Additional monthly costs for facility management and security services amounted to $9,000 and $9,000 as of March 31, 2017 and December 31, 2016, respectively. In July 2015, the Company entered into a lease agreement with CardConnect, LLC, for the use of office premises at 1000 Continental Drive, Suite 600, King of Prussia, PA 19406, USA with the lease term continuing until December 2023. The monthly base rental fee was $40,000 and $40,000 as of March 31, 2017 and December 31, 2016, respectively. Rent expense was $304,000 and $272,000 for the three months ended March 31, 2017 and 2016, respectively. The obligations under the lease agreements are payable as follows: (in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years Total $ $ Other contractual commitments In addition to the agreements described above, the Company has entered into a number of other agreements also entailing financial commitments for the future and relating mainly to services provided by third parties in connection with the conduct of clinical trials and other research and development activities. Some of these commitments are also subject to early termination clauses exercisable at the option of the Company. The remaining payments to be made under these agreements, if all milestones and other conditions are met, are estimated to be as follows: (in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years — — Total $ $ Contingencies The Company has no contingent liabilities in respect of legal claims arising in the ordinary course of business.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events
Subsequent Events	18. Subsequent Events The Company evaluated all events or transactions that occurred subsequent to March 31, 2017 through the date the unaudited consolidated financial statements were issued, and have not identified any such events material to an understanding of the unaudited consolidated financial statements.

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Summary of Significant Accounting Policies
Basis of Preparation	Basis of Preparation The unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and U.S. Securities and Exchange Commission (“SEC”) regulations for quarterly reporting. The accompanying consolidated financial information as of March 31, 2017 and for the three months ended March 31, 2016 and 2017 is unaudited. The year-end condensed balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The interim unaudited financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of March 31, 2017 and for the three months ended March 31, 2016 and 2017. The financial data and other information disclosed in these notes related to the three months ended March 31, 2016 and 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017, any other interim periods or any future year or period. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K, as filed with the SEC on March 24, 2017. The Company’s significant accounting policies are described in Note 2 of the notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016. Since the date of those financial statements, there have been no changes to the Company’s significant accounting policies.
Recent Accounting Pronouncements	Recent Accounting Pronouncements At the time of authorization of these consolidated financial statements for publication, a number of revisions, amendments and interpretations had already been published by the Financial Accounting Standards Board (FASB). None of these are expected to have a significant effect on the consolidated financial statements of the Company, except the following set out below: · In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers , an updated standard on revenue recognition. ASU 2014-09 provides enhancements to the quality and consistency of how revenue is reported by companies while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or US GAAP. The main purpose of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which a company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. In July 2015, the FASB voted to approve a one-year deferral of the effective date of ASU 2014-09, which will be effective for the Company in the first quarter of fiscal year 2018 and may be applied on a full retrospective or modified retrospective approach. ASU 2014-09 will have no impact on the Company until it begins to generate product revenue. · In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern . ASU 2014-16 explicitly requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. In connection with each annual and interim period, management will assess if there is substantial doubt about an entity’s ability to continue as a going concern within one year after the issuance date. Management will consider relevant conditions that are known, and reasonably knowable, at the issuance date. Substantial doubt exists if it is probable that the entity will be unable to meet its obligations within one year after the issuance date. Disclosures will be required if conditions give rise to substantial doubt. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. Early adoption is permitted. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In November 2015, the FASB issued ASU 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the balance sheet classification of deferred taxes and requires that all deferred taxes be presented as noncurrent. ASU 2015-17 is effective for fiscal years beginning after December 15, 2016 with early adoption permitted. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In January 2016, FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . ASU 2016-01 requires equity investments to be measured at fair value with changes in fair value recognized in net income; simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment; eliminates the requirement for public business entities to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial assets on the balance sheet or the accompanying notes to the financial statements and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. ASU 2016-01 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-01 will have on its financial statements and related disclosures. · In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods, with early adoption permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures. · In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting , which provides for simplification of certain aspects of employee share-based payment accounting including income taxes, classification of awards as either equity or liabilities, accounting for forfeitures and classification on the statement of cash flows. ASU 2016-09 will be effective for the Company in the first quarter of 2017 and will be applied either prospectively, retrospectively or using a modified retrospective transition approach depending on the area covered in this update. The impact of adopting this standard did not have a material effect on the Company’s financial position, results of operation or cash flow and related disclosures. · In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), in April 2016 issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”), and in May 2016, issued ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 Pursuant to Staff Announcements at the March 3, 2016 EITF Meeting (“ASU 2016-11”) . ASU 2016-08 clarifies principal versus agent considerations relating to when another party, along with the entity, is involved in providing a good or service to a customer. ASU 2016-08 requires an entity to determine whether the nature of its promise is to provide a good or service to a customer, or to arrange for the good or service to be provided to the customer by the other party. This determination is based upon whether the entity controls the good or service before it is transferred to the customer. When the entity that satisfies a performance obligation is the principal, the entity recognizes the gross amount of consideration as revenue. When the entity that satisfies the performance obligation is the agent, it recognizes the amount of any fee or commission as revenue. ASU 2016-10 clarifies the guidance in Topic 606 for identifying performance obligations in a contract as well as the implementation guidance pertaining to revenue recognition related to licensing arrangements. ASU 2016-11 rescinds several SEC Staff Announcements that are codified in Topic 605, including, among other items, guidance relating to accounting for consideration given by a vendor to a customer, as well as accounting for shipping and handling fees and freight services. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In May 2016, the FASB also issued ASU 2016-12, Revenue from Contracts with Customers - Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”), which provides clarification on certain topics within ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), including assessing collectability, presentation of sales taxes, the measurement date for non-cash consideration and completed contracts at transition, as well as providing a practical expedient for contract modifications at transition. The effective date and transition requirements for the amendments in ASU 2016-08, ASU 2016-10 and ASU 2016-12 are the same as the effective date and transition requirements of ASU 2014-09, which is effective for fiscal years, and for interim periods within those years, beginning after December 15, 2017. The Company is currently evaluating the impacts of this standard on its financial statements and anticipates no significant effects when the standard is adoped as of the effective date. · In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . The amendments in this ASU introduce clarifications to the presentation of certain cash receipts and cash payments in the statement of cash flows. The primary updates include additions and clarifications of the classification of cash flows related to certain debt repayment activities, contingent consideration payments related to business combinations, proceeds from insurance policies, distributions from equity method investees and cash flows related to securitized receivables. This update is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of this ASU is permitted, including in interim periods. The ASU requires retrospective application to all prior periods presented upon adoption. The Company is currently evaluating the impact, if any, that the adoption of this guidance will have on its cash flows and/or disclosures, however, the Company does not anticipate that the new guidance will have a significant impact on its financial statements and related disclosures. · In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash . ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company does not expect the adoption of the amendments to have a material effect on its financial statements and related disclosures.

Research Premium and Grant Re25

Research Premium and Grant Revenue (Tables)	3 Months Ended
	Mar. 31, 2017
Research Premium and Grant Revenue
Schedule of research premium and grant revenue	Three Months Ended (in thousands) 2016 2017 Research premium $ $ Government grants — Grants from WWFF Total $ $

Research and Development Expe26

Research and Development Expenses (Tables)	3 Months Ended
	Mar. 31, 2017
Research and Development Expenses
Schedule of research and development expenses	Three Months Ended (in thousands) 2016 2017 Research materials and purchased services $ $ Staff costs Other research and development expenses Depreciation and amortization Total $ $

General and Administrative Ex27

General and Administrative Expenses (Tables)	3 Months Ended
	Mar. 31, 2017
General and Administrative Expenses
Schedule of General and Administrative expenses	Three Months Ended (in thousands) 2016 2017 Other general and administrative expenses $ $ Staff costs Depreciation and amortization Total $ $

Other income (expense), net (Ta

Other income (expense), net (Tables)	3 Months Ended
	Mar. 31, 2017
Other income (expense), net
Schedule of other income (expense), net	Three Months Ended (in thousands) 2016 2017 Foreign exchange gain $ $ Foreign exchange losses ) ) Other Total $ $

Earnings (Loss) per Share (Tabl

Earnings (Loss) per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings (Loss) per Share
Schedule of basic earnings/losses per share	Three Months Ended (in thousands, except per share data) 2016 2017 Net loss for the period $ ) $ ) Weighted average number of shares outstanding Excluded treasury shares on March 31 — Basic loss per share $ ) $ )

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Measurement
Schedule of the financial instruments measured at fair value and classified by level according to the fair value measurement hierarchy	(in thousands) Level 1 Level 2 Level 3 Total As of December 31, 2016 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $ (in thousands) Level 1 Level 2 Level 3 Total As of March 31, 2017 Assets: Short-term investments: Available-for-sale investments $ $ $ — $ Term Deposits — — Total Assets $ $ $ — $

Long-term and current receiva31

Long-term and current receivables (Tables)	3 Months Ended
	Mar. 31, 2017
Long-term and current receivables
Schedule of long-term and current receivables	(in thousands) As of As of Deposits $ $ Total long-term receivables $ $ Research premium VAT and other taxes Receivables from grant revenue — Other receivables Total current receivables $ $ Total $ $

Short-term investments (Tables)

Short-term investments (Tables)	3 Months Ended
	Mar. 31, 2017
Short-term investments
Schedule of short-term investments	As of December 31, 2016 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $ As of March 31, 2017 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Fair Value Short-term investments: $ — $ — $ — $ — Available-for-sale investments $ $ — $ ) $ Term deposits $ $ — $ — $ Total $ $ — $ ) $

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	3 Months Ended
	Mar. 31, 2017
Cash and Cash Equivalents
Schedule of cash and cash equivalents	(in thousands) As of As of Cash on hand $ — $ — Cash at bank Total cash and cash equivalents $ $

Share-Based Payments (Tables)

Share-Based Payments (Tables)	3 Months Ended
	Mar. 31, 2017
Stock Option Plan 2007
Share-Based Payments
Schedule of movements of share options outstanding and their related weighted average exercise prices	2017 Stock Option Plan 2007 Weighted Options Aggregate Outstanding as of January 1, 2017 Granted — — Exercised ) Forfeited — — Outstanding as of March 31, 2017 $ Vested and exercisable as of March 31, 2017 $
Stock Option Plan 2015
Share-Based Payments
Schedule of movements of share options outstanding and their related weighted average exercise prices	2017 Stock Option Plan 2015 Weighted Options Aggregate Outstanding as of January 1, 2017 Granted Exercised — — Forfeited ) Outstanding as of March 31, 2017 $ Vested and exercisable as of March 31, 2017 $
Schedule of inputs to the option pricing method	Input parameters Granted on Granted on Grant date share price in $ Exercise price in $ Expected volatility % % Expected term of options 2.2 years 2.2 years Risk-free interest rate -0.777 % -0.718 % Dividend yield — —

Accrued Expenses and Other Li35

Accrued Expenses and Other Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other current liabilities	(in thousands) As of As of Research and development related costs $ $ Payroll and related costs Accounting, tax and audit services Other Total other current liabilities $ $

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments and Contingencies
Schedule of obligations payable under the lease agreements	(in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years Total $ $
Schedule of remaining payments to be made under other contractual agreements	(in thousands) As of As of No later than 1 year $ $ Later than 1 year and no later than 5 years Later than 5 years — — Total $ $

Organization and Business Act37

Organization and Business Activities (Details)	Mar. 31, 2017
Nabriva Therapeutics US, Inc.
Percentage ownership by reporting entity	100.00%
Nabriva Therapeutics Ireland DAC
Percentage ownership by reporting entity	100.00%

Organization and Business Act38

Organization and Business Activities - Liquidity (Details) $ in Millions	Mar. 31, 2017USD ($)
Cash and cash equivalents and short term investments
Cash and cash equivalents and short term investments	$ 68.2

Organization and Business Act39

Organization and Business Activities - December 2016 Financing (Details) - December 2016 Financing - Common Stock $ in Millions	Dec. 19, 2016USD ($)shares
December 2016 Financing
Number of shares sold | shares	588,127
Gross proceeds from sale of shares	$ 24.8
Net proceeds from sale of shares, after deducting underwriting fees and offering expenses	$ 20.6

Organization and Business Act40

Organization and Business Activities - IPO (Details) - USD ($) $ / shares in Units, $ in Millions	Sep. 30, 2015	Sep. 30, 2015	Sep. 23, 2015
IPO
Number of common shares represented by each ADS share			0.1
IPO, including Over-Allotment Option
IPO
For aggregate number of ADS shares issued, the aggregate number of common shares represented	1,035,000
IPO, including Over-Allotment Option | ADS
IPO
Number of shares sold	10,350,000
Gross proceeds from initial public offering	$ 106.1
Net proceeds from sale of shares, after deducting underwriting fees and offering expenses	$ 92.4
IPO
IPO
For aggregate number of ADS shares issued, the aggregate number of common shares represented			900,000
IPO | ADS
IPO
Number of shares sold			9,000,000
Shares issued price per share			$ 10.25
Over-Allotment Option
IPO
For aggregate number of ADS shares issued, the aggregate number of common shares represented		135,000
Over-Allotment Option | ADS
IPO
Number of shares sold		1,350,000
Shares issued price per share	$ 10.25	$ 10.25

Research Premium and Grant Re41

Research Premium and Grant Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Research Premium and Grant Revenue
Research premium	$ 1,505	$ 1,392
Government grants	147
WWFF Grants	26	27
Total	$ 1,678	$ 1,419

Research and Development Expe42

Research and Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Research and development expenses
Depreciation and amortisation	$ 76	$ 45
Total	12,660	13,036
Research and development expenses
Research and development expenses
Research materials and purchased services	9,608	10,184
Staff costs	2,320	1,985
Other research and development expenses	699	838
Depreciation and amortisation	33	29
Total	12,660	13,036
Other research and development expenses
Other research and development expenses
Infrastructure expenses	300	300
Advisory and external consultancy expenses	300	300
Intellectual property and trademark related expenses	$ 100	100
Travel expenses		$ 100

General and Administrative Ex43

General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
General and Administrative Expenses
Depreciation and amortisation	$ 76	$ 45
Total	4,218	3,085
General and administrative expenses
General and Administrative Expenses
Other general and administrative expenses	2,797	1,649
Staff costs	1,378	1,420
Depreciation and amortisation	43	16
Total	4,218	3,085
Other general and administrative expenses
Other general and administrative expenses
Advisory and external consultancy expenses	700	400
Tax consulting, payroll accounting, accounting and auditing expenses	200	100
Infrastructure expenses	400	300
Legal expenses	1,000	300
Travel expenses	100	100
Supervisory board fees and expenses	100	100
Other expenses	$ 300	$ 300

Post-employment benefit oblig44

Post-employment benefit obligations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Austria
Monthly contribution (as a percent)	1.53%	1.53%
Contribution costs	$ 11,000	$ 11,000
U.S.
Contribution costs	$ 51,000	$ 32,000
Percent of match, first level	100.00%	100.00%
Employee voluntary contribution, first level	3.00%	3.00%
Percent match, second level	50.00%	50.00%
Employee voluntary contribution, second level	2.00%	2.00%

Other income (expense), net (De

Other income (expense), net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Other income (expense), net
Foreign exchange gain	$ 993	$ 1,439
Foreign exchange losses	(809)	(459)
Other	22	18
Total	$ 206	$ 998

Income tax (expense) benefit (D

Income tax (expense) benefit (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income tax (expense) benefit
Income tax (expense) benefit	$ 349,000	$ (17,000)
Non-current deferred tax asset	1,232,000		$ 1,410,000
Valuation allowance - current and noncurrent	$ 58,085		$ 54,114

Earnings (Loss) per Share (Deta

Earnings (Loss) per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Basic earnings/losses per share
Net loss	$ (15,223)	$ (13,599)
Weighted average number of shares outstanding	2,720,423	2,117,895
Excluded treasury shares on March 31		2,819
Basic loss per share	$ (5.60)	$ (6.42)
Antidilutive share options
Number of outstanding share options excluded from computation of diluted earnings per share	278,579	191,496

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Short-term investments:
Transfer of assets from Level 1 to 2	$ 0	$ 0
Transfer of assets from Level 2 to 1	0	0
Recurring
Short-term investments:
Available-for-sale investments	41,031	51,076
Term Deposits	30	30
Total Assets	41,061	51,106
Level 1 | Recurring
Short-term investments:
Available-for-sale investments	15,001	15,017
Term Deposits	30	30
Total Assets	15,031	15,047
Level 2 | Recurring
Short-term investments:
Available-for-sale investments	26,030	36,059
Total Assets	$ 26,030	$ 36,059

Long-term and current receiva49

Long-term and current receivables (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Long-term receivables
Deposits	$ 424	$ 420
Total long-term receivables	424	420
Current receivables
Research premium	6,910	5,346
VAT and other taxes	316	46
Receivables from grant revenue		144
Other receivables	222	25
Total current receivables	7,448	5,561
Total long-term and current receivables	7,872	5,981
Receivables additional disclosures
Past due receivables	0	0
Impaired receivables	0	0
Pledged receivables	$ 0	$ 0

Short-term investments (Details

Short-term investments (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Short-term investments
Amortized Cost	$ 41,077	$ 51,124
Unrealized Losses	(16)	(18)
Fair Value	41,061	51,106
Available-for-sale investments
Short-term investments
Amortized Cost	41,047	51,094
Unrealized Losses	(16)	(18)
Fair Value	41,031	51,076
Term deposits
Short-term investments
Amortized Cost	30	30
Fair Value	$ 30	$ 30

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Cash and Cash Equivalents
Cash at bank	$ 27,166	$ 32,778
Total cash and cash equivalents	$ 27,166	$ 32,778	$ 29,453	$ 36,446

Share-Based Payments - Stock Op

Share-Based Payments - Stock Option Plan 2007 (Details) - Stock Option Plan 2007 - USD ($)	3 Months Ended
	Mar. 31, 2017	Sep. 12, 2007
Share-Based Payments
Number of awards that can be granted		29,889
Vested option rights outstanding	$ 1,087,000
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)	$ 7.32
Exercised (in dollars per share)	7.32
Outstanding balance at end of year (in dollars per share)	7.32
Vested and exercisable balance at end of year (in dollars per share)	$ 7.32
Options
Outstanding at beginning of year (in shares)	10,996
Exercised (in shares)	(5,156)
Outstanding at end of year (in shares)	5,840
Vested and exercisable at end of year (in shares)	5,712
Aggregate Intrinsic value
Outstanding at end of year (in dollars)	$ 1,112,000
Vested and exercisable at end of year (in dollars)	1,086,000
Total intrinsic value of options exercised	$ 943,000
Other disclosures
Weighted-average remaining contractual life	2 months 12 days
Share-based compensation expense (in dollars)	$ 15,000
Weighted average of share price at the date of exercise of options (in dollars per share)	$ 97.67
Options
Share-Based Payments
Vesting period	4 years
Minimum percentage of shares or asset sale to permit exercise	50.00%
Options | First year
Share-Based Payments
Vesting period	1 year
Percentage that vests during the period	25.00%
Options | Second year
Share-Based Payments
Vesting period	2 years
Percentage that vests during the period	25.00%
Options | Third and fourth years
Share-Based Payments
Vesting period	4 years
Percentage that vests during the period	50.00%
Monthly vesting percentage	2.083%

Share-Based Payments - Stock 53

Share-Based Payments - Stock Option Plan 2015 (Details) - Stock Option Plan 2015 - USD ($) $ / shares in Units, $ in Thousands	Mar. 21, 2017	Feb. 07, 2017	Mar. 31, 2017	Aug. 25, 2016	Sep. 23, 2015	Apr. 02, 2015
Share-Based Payments
Number of awards that can be granted				346,235	177,499	95,000
Exercise period			10 years
Vested option rights outstanding			$ 4,214
Weighted average exercise price in $ per share
Outstanding balance at beginning of year (in dollars per share)			$ 78.25
Granted (in dollars per share)	$ 110	$ 85	85.51
Forfeited (in dollars per share)			88
Outstanding balance at end of year (in dollars per share)			80.65
Vested and exercisable balance at end of year (in dollars per share)			$ 77.12
Options
Outstanding at beginning of year (in shares)			179,436
Granted (in shares)			102,560
Forfeited (in shares)			(9,257)
Outstanding at end of year (in shares)			272,739
Vested and exercisable at end of year (in shares)			62,805
Aggregate Intrinsic value
Outstanding at end of year (in dollars)			$ 12,255
Vested and exercisable at end of year (in dollars)			$ 3,926
Options
Share-Based Payments
Vesting period			4 years
Options | First year
Share-Based Payments
Vesting period			1 year
Percentage that vests during the period			25.00%
Options | Second, third and fourth years
Share-Based Payments
Vesting period			4 years
Percentage that vests during the period			75.00%
Monthly vesting percentage			2.083%

Share-Based Payments - Stock 54

Share-Based Payments - Stock Option Plan 2015 Outstanding and Fair Value (Details) - Stock Option Plan 2015 - USD ($)	Mar. 21, 2017	Feb. 07, 2017	Mar. 31, 2017
Share-Based Payments
Share-based compensation expense (in dollars)			$ 1,800,000
Income tax benefit			$ 200,000
Weighted-average grant date fair value (in dollars per share)			$ 32.47
Granted (in shares)			102,560
Fair Value Assumptions
Grant date share price (in dollars per share)	$ 110	$ 85
Exercise price (in dollars per share)	$ 110	$ 85	$ 85.51
Expected volatility (as a percent)	66.00%	68.00%
Expected option term (in years)	2 years 2 months 12 days	2 years 2 months 12 days
Risk-free interest rate (as a percent)	(0.718%)	(0.777%)
Other disclosures
Weighted-average remaining contractual life			9 years 10 months 24 days
Total unrecognized compensation related to non-vested options (in dollars)			$ 8,000,000
Period of recognition of total unrecognized compensation related to options			2 years 2 months 12 days

Share-Based Payments - Founders

Share-Based Payments - Founders' Program 2007 (Details) - Founder's Program 2007	1 Months Ended		24 Months Ended
	Feb. 29, 2008shares	Nov. 30, 2007shares	Feb. 28, 2010$ / sharesshares	Mar. 31, 2017€ / sharesshares
Share-Based Payments
Outstanding				623
Outstanding options exercise price (in dollars per share) | € / shares				€ 1
Percentage that vests during the period	25.00%	25.00%	50.00%
Vested (in shares)	155	156
Monthly vesting percentage			2.083%
Shares vested monthly (in shares)			13
Weighted-average grant date fair value (in dollars per share) | $ / shares			$ 144.23

December 2016 Financing (Detail

December 2016 Financing (Details) $ / shares in Units, $ in Millions	Dec. 19, 2016USD ($)$ / sharesshares	Dec. 14, 2016€ / sharesshares	Sep. 23, 2015shares	Dec. 19, 2016€ / sharesshares
December 2016 Financing
Number of common shares represented by each ADS share			0.1
December 2016 Financing
December 2016 Financing
Aggregate ADS shares subscribed for by holders of ADS	1,592,750
Aggregate number of common shares represented by the aggregate ADS shares subscribed for by holders of ADS	159,275
Number of common shares represented by each ADS share	0.1
Aggregate number of common shares subscribed for by holders of common shares	102,077
December 2016 Financing | ADS | ADS Right
December 2016 Financing
Number of rights into which each share of stock converted	0.276
Number of shares into which each right was entitled	1			1
Per share exercise price of right | (per share)	$ 4.32			€ 4.014
December 2016 Financing | Common Stock
December 2016 Financing
Number of shares sold	588,127
Gross proceeds from sale of shares | $	$ 24.8
Net proceeds from sale of shares, after deducting underwriting fees and offering expenses | $	$ 20.6
December 2016 Financing | Common Stock | Common Share Right
December 2016 Financing
Number of shares into which each right was entitled	0.276			0.276
Per share exercise price of right | € / shares				€ 40.14
December 2016 Financing Underwriting | Common Stock
December 2016 Financing
Number of shares sold		326,775
Shares issued price per share | € / shares		€ 40.14

Accrued Expenses and Other Li57

Accrued Expenses and Other Liabilities - Obligation (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Collective bargaining arrangement, Chemical industry
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Discount rate	1.30%
Annual salary increase rate	3.00%
Collective bargaining arrangement, Chemical industry | Minimum
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Retirement age for men (in years)	61 years 6 months
Retirement age for women (in years)	56 years 6 months
Collective bargaining arrangement, Chemical industry | Maximum
Principle actuarial assumptions used in calculation of the company's obligations for jubilee payments
Retirement age for men (in years)	65 years
Retirement age for women (in years)	65 years
Other non-current liabilities
Other non-current liabilities
Provision for jubilee payments obligation	$ 113,000	$ 107,000

Accrued Expenses and Other Li58

Accrued Expenses and Other Liabilities - Accrued expenses and other current liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Components of accrued expenses and other current liabilities:
Research and development related costs	$ 8,739	$ 8,716
Payroll and related costs	1,461	2,150
Accounting, tax and audit services	471	484
Other	882	1,976
Total other current liabilities	$ 11,553	$ 13,326

Commitments and Contingencies -

Commitments and Contingencies - Lease Arrangements (Details) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2007
Lease Arrangements
Rent expense			$ 304,000	$ 272,000
Obligations payable under the lease agreement:
No later than 1 year	$ 1,252,000	$ 1,484,000	1,252,000
Later than 1 year and no later than 5 years	2,572,000	2,536,000	2,572,000
Later than 5 years	515,000	507,000	515,000
Total	4,339,000	4,527,000	$ 4,339,000
Lease agreement for use of business and research premises at Vienna
Lease Arrangements
Term of the lease agreement, under which it can only be terminated under certain conditions					10 years
Monthly costs for facility management and security services	9,000	9,000
Lease agreement for use of business and research premises at Vienna | Premises and laboratory furniture
Lease Arrangements
Monthly rent	84,000	85,000
Lease agreement for use of office premises at King of Prussia, Suite 600
Lease Arrangements
Monthly rent	$ 40,000	$ 40,000

Commitments and Contingencies60

Commitments and Contingencies - Other contractual commitments and Contingencies (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Remaining payments to be made under other contractual agreements
No later than 1 year	$ 45,575	$ 51,685
Later than 1 year and no later than 5 years	5,290	6,241
Total	50,865	$ 57,926
Contingencies
Contingent liabilities	$ 0